Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion

BACKGROUND: Osimertinib is a standard first-line treatment for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Although malignant pleural effusion (PE) is a common clinical problem in NSCLC, information about the efficacy of osimertinib in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Nokihara, Hiroshi, Ogino, Hirokazu, Mitsuhashi, Atsushi, Kondo, Kensuke, Ogawa, Ei, Ozaki, Ryohiko, Yabuki, Yohei, Yoneda, Hiroto, Otsuka, Kenji, Nishioka, Yasuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158359/
https://www.ncbi.nlm.nih.gov/pubmed/35650550
http://dx.doi.org/10.1186/s12885-022-09701-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158359/
https://www.ncbi.nlm.nih.gov/pubmed/35650550
http://dx.doi.org/10.1186/s12885-022-09701-2

Ejemplares similares